Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): July 29, 2019



(Exact Name of Registrant as Specified in Charter)


Delaware   000-21990   13-3679168

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


29397 Agoura Road Suite 107

Agoura Hills, CA 91301

(Address of Principal Executive Offices)


Registrant’s telephone number, including area code: (605) 635-7000



(Former Name of Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]






On July 29, 2019 Mateon Therapeutics, Inc. (the “Company”) filed a current report on Form 8-K with the Securities and Exchange Commission, reporting that the Company had engaged Squar Milner LLP as its independent registered accounting firm. This amendment on Form 8-K/A supplements the information contained in the original report.


Item 4.01. Change in Registrant’s Certifying Accountant.


On September 4, 2019 the Company received a letter dated July 29, 2019 from OUM & Co, LLP (“OUM”), the Company’s prior registered independent account firm, addressed to the Securities and Exchange Commission stating that OUM is in agreement with the Company’s disclosure in Item 4.01 of the current report on Form 8-K filed by the Company on July 29, 2019. A copy of OUM’s letter is filed with this report as Exhibit 16.1.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Description   Incorporation by reference
16.1   Letter of OUM & Co, LLP dated July 29, 2019.   Filed herewith.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 6, 2019 MATEON THERAPEUTICS, INC.
  By: /s/ Vuong Trieu
  Name: Vuong Trieu
  Title: Chief Executive Officer





July 29, 2019


Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549


We have been furnished with a copy of Item 4.01 of Form 8-K for the event that occurred on July 29, 2019, to be filed by Mateon Therapeutics, Inc. We agree with the statements made in paragraph 2 of that Item 4.01 insofar as they relate to OUM & Co. LLP.


Very truly yours,


/s/ OUM & CO. LLP


San Francisco, California

July 29, 2019